[8-K] Sagimet Biosciences Inc. Reports Material Event

Rhea-AI Filing Summary

Sagimet Biosciences Inc. reported that it has updated its investor slide presentation and made it available as a new version for use in upcoming meetings with investors. The company also announced positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, with a thyroid hormone receptor beta agonist, resmetirom. These early-stage data relate to how the drugs are processed in the body when used together and are being shared through a press release and updated investor materials attached as exhibits.

Insights

Biotech and clinical development analyst

Sagimet reports positive Phase 1 pharmacokinetic data for a drug combination and refreshes investor materials.

Sagimet Biosciences disclosed positive Phase 1 pharmacokinetic results for a combination of denifanstat, its oral once-daily fatty acid synthase inhibitor, and the thyroid hormone receptor beta agonist resmetirom. Phase 1 pharmacokinetic trials focus on how drugs are absorbed, distributed, metabolized and eliminated, especially when used together.

The company also refreshed its investor presentation, which representatives plan to use in meetings with investors. The updated deck and the press release describing the trial results are provided as exhibits, giving more detailed scientific and strategic context for the combination program.

For investors, the key milestone is the confirmation that the combination produced positive pharmacokinetic findings, which can support further clinical development decisions. Subsequent updates in future company communications will be important to understand how these data translate into later-stage trials and potential clinical benefit.

false 0001400118 0001400118 2025-12-18 2025-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2025

SAGIMET BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41742	20-5991472
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Sagimet Biosciences Inc.

155 Bovet Road, Suite 303,

San Mateo, California 94402

(Address of principal executive offices, including zip code)

(650) 561-8600

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Series A Common Stock, $0.0001 par value per share	SGMT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On December 18, 2025, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 furnished herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On December 18, 2025, the Company issued a press release announcing positive results in the Phase 1 pharmacokinetic trial of a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, and a thyroid hormone receptor beta agonist, resmetirom. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Document
99.1		Investor Presentation of Sagimet Biosciences Inc., dated December 18, 2025
99.2		Press Release of Sagimet Biosciences Inc., dated December 18, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sagimet Biosciences Inc.
Date: December 18, 2025	By:	/s/ David Happel
		David Happel
		Chief Executive Officer

FAQ

What did Sagimet Biosciences (SGMT) announce in its latest report?

Sagimet Biosciences announced that it updated its investor slide presentation and reported positive results from a Phase 1 pharmacokinetic trial of a combination of denifanstat and resmetirom. The updated presentation and a press release describing the trial are attached as exhibits.

What clinical progress did Sagimet Biosciences (SGMT) report for denifanstat?

The company reported positive results in a Phase 1 pharmacokinetic trial evaluating a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, with the thyroid hormone receptor beta agonist resmetirom.

What new materials did Sagimet Biosciences (SGMT) make available to investors?

Sagimet Biosciences provided an updated investor presentation dated December 18, 2025 as an exhibit, which representatives plan to use in various investor meetings, along with a press release detailing the Phase 1 pharmacokinetic trial results.

How is Sagimet Biosciences (SGMT) sharing information about the Phase 1 trial results?

The company is sharing information through a press release attached as Exhibit 99.2 and through an updated investor presentation attached as Exhibit 99.1, both dated December 18, 2025.

What type of trial produced the positive results reported by Sagimet Biosciences (SGMT)?

The positive results came from a Phase 1 pharmacokinetic trial studying the combination of denifanstat and resmetirom, focusing on how the two drugs behave in the body when administered together.

Which exhibits did Sagimet Biosciences (SGMT) include with this disclosure?

The company included an investor presentation as Exhibit 99.1, a press release announcing the positive Phase 1 pharmacokinetic trial results as Exhibit 99.2, and a cover page interactive data file as Exhibit 104.